Sign In
Buy COGT
$32.26
-0.500 (-1.53%)
At Close: Jun 03, 2026
Bezuclastinib combination is first treatment ever to demonstrate statistically significant advantage against active comparator in GIST patients; median PFS of 16.5 months versus 9.2 months (HR=0.50, C
NDA acceptance with Priority Review builds upon previous assignment of Breakthrough Therapy Designation and Real-Time Oncology Review following Phase 3 PEAK results; PDUFA date set for November 30, 20
Cogent Biosciences Announces Participation in the 2026 Jefferies Global Healthcare Conference
08:00am, Wednesday, 27'th May 2026
WALTHAM, Mass. and BOULDER, Colo.
Cogent Biosciences Announces Multiple Presentations at the European Hematology Association (EHA) 2026 Congress
09:30am, Tuesday, 12'th May 2026
WALTHAM, Mass. and BOULDER, Colo., May 12, 2026 (GLOBE NEWSWIRE) -- Cogent Biosciences, Inc. (Nasdaq: COGT), a biotechnology company focused on developing precision therapies for genetically defined d
Cogent Biosciences Reports Recent Business Highlights and First Quarter 2026 Financial Results
08:00am, Tuesday, 05'th May 2026
- Planning for dual launches of bezuclastinib in Systemic Mastocytosis and Gastrointestinal Stromal Tumors (GIST) - Pivotal data from Phase 3 PEAK trial in GIST patients selected for oral presentation
WALTHAM, Mass. and BOULDER, Colo.
Cogent Biosciences Announces Poster Presentations at the American Association for Cancer Research (AACR) Annual Meeting 2026
08:00am, Friday, 17'th Apr 2026
– Updated presentation on Cogent's potent pan-KRAS(ON) inhibitor, CGT1263, showcasing its selectivity profile which could lead to reduction in skin toxicity associated with multi-RAS inhibitors
Cogent Biosciences: Blockbuster Potential, Premium Valuation, Still A 'Buy'
01:16pm, Thursday, 02'nd Apr 2026
Cogent Biosciences, Inc. maintains a Buy rating as bezuclastinib demonstrates blockbuster potential in GIST and systemic mastocytosis (SM) indications. Bezuclastinib nearly doubled median PFS in 2L GI
Head to Head Contrast: Cogent Biosciences (NASDAQ:COGT) versus GT Biopharma (NASDAQ:GTBP)
01:59am, Thursday, 02'nd Apr 2026
Cogent Biosciences (NASDAQ: COGT - Get Free Report) and GT Biopharma (NASDAQ: GTBP - Get Free Report) are both medical companies, but which is the superior stock? We will compare the two companies bas
Cogent Biosciences Announces Submission of New Drug Application for Bezuclastinib in Gastrointestinal Stromal Tumors (GIST)
08:00am, Wednesday, 01'st Apr 2026
WALTHAM, Mass. and BOULDER, Colo., April 01, 2026 (GLOBE NEWSWIRE) -- Cogent Biosciences, Inc. (Nasdaq: COGT), a biotechnology company focused on developing precision therapies for genetically defin
Cogent Biosciences, Cigna Group among top healthcare stocks, according to UBS analysts
04:02pm, Monday, 30'th Mar 2026
UBS analysts have outlined a set of high-conviction healthcare ideas where they believed the market was underappreciating earnings durability and the scale of upcoming catalysts, focusing on stocks ba
This $116 Million Buy Joins a 360% Stock Run and Seemingly Signals Conviction in a Key Drug Launch
07:13pm, Saturday, 21'st Mar 2026
RTW Investments added 4,124,755 Cogent Biosciences shares in the fourth quarter; the estimated trade size was $115.95 million. Meanwhile, the quarter-end stake value increased by $219.88 million, refl
High-Flying Biotech Stock Up 360% Faces $48 Million Trim but Remains This Fund's Largest Holding
06:23pm, Saturday, 21'st Mar 2026
Kynam Capital sold 1,720,949 shares of Cogent Biosciences in the fourth quarter; the estimated transaction value was $48.38 million. Meanwhile, the position's quarter-end value changed by $105.74 mill
Biotech Stock Up 372% Gets Sold as New Pick Rises 40% in 2026
12:07pm, Friday, 20'th Mar 2026
Boone Capital Management sold 945,042 shares of Cogent Biosciences in the fourth quarter. As a result, the quarter-end position value decreased by $13.57 million.
COGT Rise as FDA Accepts Bezuclastinib NDA in Non-Advanced SM
12:40pm, Tuesday, 17'th Mar 2026
Cogent Biosciences jumps after FDA accepts bezuclastinib NDA for treating non-advanced SM, with a decision due by Dec. 30, 2026.
